Diabetes is a common disease characterized by impaired glycemic control in the
body. High blood glucose readings are any fasting blood glucose more than or
equal to 126 mg/dl, random blood glucose more than or equal to 200 mg/dl, or
A1c level greater than or equal to 6.5%. We used a retrospective, chart review
study design to collect the A1c readings in patients using Dapagliflozin 10mg.
The total sample size was 107 participants. 57 participants were on Dapagliflozin,
33 on Semaglutide, and 17 were on a combination of Semaglutide and
Dapagliflozin. Weight significantly decreased in participants using Dapagliflozin
and Semaglutide combination (p<0.001) compared to those using Semaglutide
alone (p<0.001). Additionally, HbA1c significantly decreased among participants
using Dapagliflozin and Semaglutide (p<0.001) and those using Dapagliflozin
alone (p<0.001). Even though SGLT-2 inhibitors weakly reduce HbA1c, we have
found in our study that Dapagliflozin has significantly decreased A1c in addition
to a reduction in weight especially among females.
Keywords: Type 2 diabetes mellitus, hba1c, semaglutide, dapagliflozin, sglt-2
inhibitors